According to the published NCHS report: “Changes in the prevalence of obesity and severe obesity between the two most recent survey cycles, 2017–March 2020 and August 2021–August 2023, were not significant.” 3/ www.cdc.gov/nchs/product...

I don’t think we’ve seen large scale (mass) use of GLP-1 drugs across enough populations and for long enough to make any bold assertions yet about their population-wide effects (I have 2 friends whose lives were totally transformed by these drugs, so clinically they can have big impact, for sure)

It’s also worth noting the nominal (but not significant) *increase* in severe obesity (BMI>40), the group in theory would be among the most likely to be prescribed drugs like Ozempic/Wegovy for diabetes or weight loss. 4/